G35.9
Conditions
Interventions
Group 1: hospitalized patients, intrathecal applikation, Triamcinolon acetonide (Volon A), consecutive therapy-cycles every 3 months, 40-80 mg Volon A every other day 3-5-times in every cycle, observ
Sponsors
Universitätsmedizin Rostock
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Patients diagnosed with multiple scleroses, who are undergoing an antispastic symptomatic treatment with the intrathecally applicated corticosteroid triamcinolone acetonide. All patients had to be in a clinically stable condition at the beginning of the trial.
Exclusion criteria
Exclusion criteria: Clinically unstable condition. Abandonment of the triamcinolone acetonide treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary outcome is the investigation of the surrogates NfH, Tau-Protein, Protein S-100B in the cerebrospinal fluid of multiple sclerosis patients. The surrogates are measured in the cerebrospinal fluid according to the specific ELISA-methods. The cerebrospinal fluid is acquired within a cyclic antispastic therapy with triamcinolone acetnide. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcome of this trial are the results of clinical parameters: Expanded Disability Status Scale, Ashworthscale, Walking distance, timed 25-Foot Walk, bladder function, qualitiy of life. The parameters of every patient are measured within the hospitalization during the triamcinolone therapy by physicians and physiotherapists of each clinic. | — |
Countries
Germany
Contacts
Public ContactU.K. Zettl
Universitätsklinikum Rostock AöRZentrum für NervenheilkundeKlinik für Neurologie und PoliklinikSektion: Neuroimmunologie
Outcome results
None listed